Breelyn Wilky, MD
Hematology & Oncology · Aurora, CONPI 1861539751
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Deciphera Pharmaceuticals Inc. at 39.1% of the total. Reporting peaked in 2024 at $18,673 and has fallen 81.0% since, to $3,557 in 2025.
Across 52 payments — averaging $882.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Deciphera Pharmaceuticals Inc.$18K
- Boehringer Ingelheim International GmbH$12K
- Daiichi Sankyo Inc.$8K
- Aadi Bioscience, Inc.$4K
- GSK$3K
- Boehringer Ingelheim$1K
- plus $319 from 2 others
Across 194 payments — averaging $7617.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Deciphera Pharmaceuticals Inc.$666K
- Merck$434K
- Exelixis Inc.$145K
- Blueprint Medicines Corporation$136K
- Springworks Therapeutics, Inc.$68K
- Boehringer Ingelheim$30K
- plus $311 from 1 others
What the payments were for
- Consulting fees$23,04850%
- Speaking & faculty fees$18,04539%
- Travel & lodging$2,6836%
- Food & beverage$1,8314%
- Education$90%
- Gifts$2581%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Deciphera Pharmaceuticals Inc. | 21 | $17,955 |
| Boehringer Ingelheim International GmbH | 3 | $12,310 |
| Daiichi Sankyo Inc. | 13 | $7,977 |
| Aadi Bioscience, Inc. | 5 | $3,502 |
| GSK | 1 | $2,600 |
| Boehringer Ingelheim | 7 | $1,210 |
| Exelixis Inc. | 1 | $162 |
| Beone Medicines USA, Inc. | 1 | $157 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$45,873 in reported general payments places this provider in the 80th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OgsiveoNirogacestat Hydrobromide | 12 | $337,244 |
| Sunitinib Malate | 35 | $222,130 |
| GleevecImatinib Mesylate | 22 | $143,924 |
| Pazopanib Hcl | 11 | $78,671 |
| Imatinib Mesylate | 37 | $3,655 |
| Celecoxib | 11 | $2,101 |
| Dexamethasone | 26 | $881 |
| Ondansetron OdtOndansetron | 16 | $409 |
| Oxycodone Hcl | 23 | $215 |
| Prochlorperazine Maleate | 16 | $129 |
| Gabapentin | 13 | $99 |
| Ondansetron Hcl | 16 | $82 |
| Methylprednisolone | 11 | $69 |
| Prednisone | 14 | $53 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Aurora
- John BurkeAurora$321K
- Douglas ReznickAurora$294K
- Daniel PollyeaAurora$274K
- Sami DiabAurora$134K
- Manali KamdarAurora$129K
- Bradley HaverkosAurora$120K
- Sujatha NallapareddyAurora$112K
- Tomer MarkAurora$96K
- Ara MetjianAurora$89K
- Ryan WeightAurora$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.